| Literature DB >> 26257337 |
Yanxia Zhang1, Mei Fan1, Qingzhong Wang1, Guang He2, Yingmei Fu1, Huafang Li3, Shunying Yu1.
Abstract
Disturbances in glutamate signaling caused by disruption of N-methyl-D-aspartate-type glutamate receptor (NMDAR) have been implicated in schizophrenia. Findings suggested that miR-219, miR-132 and miR-107 could involve in NMDAR signaling by influencing the expression of pathway genes or the signaling transmission and single nucleotide polymorphisms (SNPs) within miRNA genes or miRNA target sites could result in their functional changes. Therefore, we hypothesized that SNPs in miRNAs and/or their target sites were associated with schizophrenia. 3 SNPs in hsa-pri-miR-219/132/107 and 6 SNPs in 3'UTRs of GRIN2A/2B/3A and CAMK2G were selected and genotyped in a case-control study of 1041 schizophrenia cases and 953 healthy controls in Chinese Han population. In the present study, GRIN2B rs890 showed significant associations with schizophrenia. Further functional analyses showed that the rs890 variant C allele led to significantly lower luciferase activity, compared with the A allele. MDR analysis showed that a 4-locus model including rs107822, rs2306327, rs890 and rs12342026 was the best model. These findings suggest that GRIN2B may be associated with schizophrenia and interaction effects of the polymorphisms in hsa-miR-219, CAKM2G, GRIN2B and GRIN3A may confer susceptibility to schizophrenia in the Chinese Han population.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26257337 PMCID: PMC4530343 DOI: 10.1038/srep12984
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Possible roles of miRNAs in NMDA signaling pathway associated with SCZ.
Figure 2The locations of 3 SNPs in the pri-miRNA transcripts.
The locations of SNPs in pri-miRNAs are depicted on black line at the upstream (negative base count, ‘–’) or downstream (positive base count, ‘+’) of the pre-miRNA. The figure is not drawn to scale.
SNPs in 3′UTR of NMDARs and CAMK2G genes (GRch38).
| Gene | 3′UTR length | SNPs in 3′UTR | Chr. Location | MAF |
|---|---|---|---|---|
| GRIN3A | 3821 bp | rs16920487 (A > T) | 9:101571102 | 0.068 |
| rs12342026 (G > A) | 9:101571582 | 0.284 | ||
| GRIN2A | 9739 bp | rs1420040 (A > G) | 16:9756540 | 0.411 |
| GRIN2B | 1307 bp | rs1805502 (A > G) | 12:13561247 | 0.212 |
| rs890 (A > C) | 12:13562374 | 0.23 | ||
| CAMK2G | 2017 bp | rs2306327 (A > T) | 10:73814020 | 0.102 |
The distribution of alleles and genotypes for 7 SNPs in SCZ and control subjects.
| SNP | Case N(freq) | Control N(freq) | OR (95%CI) | P-value | P-value* |
|---|---|---|---|---|---|
| rs2296616(A > G) ( | 1034 | 935 | |||
| G | 141(0.068) | 155(0.083) | 0.81(0.64–1.03) | 0.080 | 0.560 |
| A | 1927(0.932) | 1715(0.917) | 1.24(0.97–1.57 | ||
| AA | 898(0.868) | 784(0.838 | 1.00 | 0.150 | 1.050 |
| AG | 131(0.127) | 147(0.157) | 0.78(0.60–1.00) | ||
| GG | 5(0.005) | 4(0.004) | 0.78(0.29–4.08) | ||
| rs107822(T > C) ( | 1035 | 921 | |||
| C | 739(0.357) | 735(0.399) | 0.049 | ||
| T | 1331(0.643) | 1107(0.601) | |||
| TT | 432(0.417) | 335(0.364) | 1 | 0.189 | |
| CT | 467(0.451) | 437(0.475) | 0.83(0.68–1.01) | ||
| CC | 136(0.131) | 149(0.162) | |||
| rs3803808(G > A) ( | 1021 | 938 | |||
| A | 1074(0.526) | 955(0.509) | 1.07(0.94–1.21) | 0.290 | 2.030 |
| G | 968(0.474) | 921(0.491) | 0.93(0,83–1.06) | ||
| GG | 236(0.231) | 239(0.255) | 1.00 | 0.474 | 3.318 |
| AG | 496(0.486) | 443(0.472) | 0.99(0.80–1.23) | ||
| AA | 289(0.283) | 256(0.273) | 0.87(0.68–1.12) | ||
| rs1420040(A > G) ( | 1036 | 920 | |||
| G | 862(0.416) | 767(0.417) | 1.00(0.88–1.14) | 0.958 | 6.706 |
| A | 1210(0.584) | 1073(0.417) | 1.00(0.88–1.14) | ||
| AA | 354(0.342) | 314(0.341) | 1.00 | 1.000 | 7.000 |
| AG | 502(0.485) | 445(0.484) | 1.00(0.82–1.22) | ||
| GG | 180(0.174) | 161(0.175) | 0.99(0.76–1.29) | ||
| rs890(A > C) ( | 1038 | 938 | |||
| C | 457(0.220) | 484(0.258) | |||
| A | 1619(0.780) | 1392(0.742) | |||
| AA | 617(0.594) | 520(0.554) | 1.00 | ||
| AC | 385(0.371) | 352(0.375) | 0.92(0.77–1.11) | ||
| CC | 36(0.035) | 66(0.007) | |||
| rs12342026(G > A) ( | 1029 | 928 | |||
| A | 502(0.244) | 491(0.265) | 0.90(0.78–1.04) | 0.139 | 0.973 |
| G | 1556(0.756) | 1365(0.735) | 1.11(0.96–1.28) | ||
| GG | 595(0.578) | 494(0.532) | 1.00 | 0.071 | 0.497 |
| AG | 366(0.356) | 377(0.406) | 0.81(0.67–0.97) | ||
| AA | 68(0.066) | 57(0.061) | 0.99(0.68–0.99) | ||
| rs2306327(A > T) ( | 1039 | 935 | |||
| T | 225(0.108) | 203(0.109) | 1.00(0.81–1.22) | ||
| A | 1853(0.892) | 1667(0.891) | 1.00(0.82–1.23) | 0.978 | 6.846 |
| AA | 822(0.791) | 743(0.795) | 1.00 | ||
| AT | 209(0.201) | 181(0.194) | 0.04(0.84–1.30) | 0.608 | 4.256 |
| TT | 8(0.008) | 11(.0.12) | 0.66(0.26–1.64) |
Bold value indicates significant result (P < 0.05).
P* is corrected by Bonferroni correction.
MDR interaction models for schizophrenia.
| No. of loci in model | SNPs included in the best combination in each model | Training accuracy | Testing accuracy | CV consistency | OR(95%CI) | P value |
|---|---|---|---|---|---|---|
| 1 | rs107822 | 0.5332 | 0.5086 | 6/10 | 1.31(1.09–1.57) | 0.0036 |
| 2 | rs107822, rs890 | 0.5530 | 0.5460 | 9/10 | 1.78(1.38–3.04) | <0.0001 |
| 3 | rs107822, rs2306327, rs12342026 | 0.5712 | 0.5308 | 8/10 | 1.83(1.52–2.20) | <0.0001 |
| 4 | rs107822,rs2306327,rs890,rs12342026 | 0.5922 | 0.5506 | 10/10 | 2.35(1.94–2.85) | <0.0001 |
aOdds ratio represents the odds of schizophrenia in the ‘‘high risk’’ group compared to the ‘‘low risk’’ group identified by MDR.
bP value is corrected by a 1000-fold permutation test.
The relative firefly luciferase activities were normalized against the Renilla luciferase activities.
| sample | firefly/Renilla activity | ||
|---|---|---|---|
| pGL3-promoter-C | pGL3-promoter-A | pGL3-promoter | |
| 1 | na | na | 0.466 (1223800/2626100) |
| 2 | 0.241(199510/828420) | 0.325 (151250/465040) | 0.388 (1400200/3608500) |
| 3 | 0.244(255660/1047900) | 0.326 152230/466620) | 0.414(578670/1399100) |
| 4 | 0.255 387070/1517500) | 0.365 139790/382850) | 0.414 (677260/1635100) |
| 5 | 0.251 379830/1512200) | 0.380(207090/545180) | 0.399(894590/2242900) |
| 6 | 0.227(435650/1915700) | 0.366(84295/230320) | 0.430 (1902800/4420000) |
Figure 3The luciferase activity of the three constructs transfected in HEK293 were graphed after normalization against the plasmid pRL-SV40 expressing the Renilla luciferase gene.
Data of the control plasimid (contained the pGL3 promoter, rather than the GRIN2B 3′UTR.) is presented as mean with SEM of n = 6 samples. Data of both 3′UTR constructs (pGL3-promoter-A and pGL3-promoter-C) are presented as means with SEM of n = 5 sample espectively. Comparisons were determined using ANOVA with post-hoc comparisons ***p < 0.001, One-way ANOVA test. Error bars are standard error.The luciferase activities of 3′-UTR constructs were significantly (p < 0.001) reduced compared with the pGL3 -Promoter vector 24 h after transfection, A mutant-type 3′-UTR construct (pGL3-promoter-C) showed lower (p < 0.001) activity than the wild-type 3′-UTR construct (pGL3-promoter-A). The relative firefly luciferase activities were normalized against the Renilla luciferase activities.